Valneva’s Shigella vaccine clears an early efficacy test
S4V2 reduced illness in a controlled human challenge study and produced immune responses in infants. Valneva has not disclosed the effect size or chosen the next development step.
Valneva has reported results from two Phase 2 studies of S4V2, its four-strain Shigella vaccine candidate. One study enrolled 110 nine-month-old infants in Kenya to assess safety and immune response. A separate U.S. study enrolled about 120 healthy adults and exposed vaccinated participants or placebo recipients to one Shigella strain under controlled conditions.
In infants, both dose levels had a favourable safety and tolerability profile. Most adverse events were mild or moderate and did not differ statistically from the control vaccine. After two doses, antibody levels increased significantly against all four targeted strains and remained above baseline six months later. Valneva nevertheless said the dose and schedule need further evaluation to improve the breadth and strength of the response.
The adult challenge study met its primary endpoint: S4V2 produced a statistically significant reduction in shigellosis caused by the tested S. sonnei strain compared with placebo. That is useful early evidence of protection, not yet a complete measure of clinical benefit. The release did not give the size of the reduction, and analysis of efficacy and immune response is still continuing.
There is no licensed Shigella vaccine, so a successful programme could address a real medical need. Commercial relevance remains distant, however. The adult result concerns a controlled challenge with one strain, while the infant study measured immune responses rather than disease prevention. Valneva is still reviewing the full data before deciding the development path. The next useful evidence will be the effect size, a defined later-stage trial and proof of protection in the intended population.
Sources
- Valneva reports Phase 2 results for S4V2 Published
